Annual screening for prostate cancer did not reduce mortality from prostate cancer

Canfield, Steven E.
June 2009
ACP Journal Club;6/23/2009, Vol. 150 Issue 6, p2
Academic Journal
The article discusses annual screening for prostate cancer in men in the age group of 55 to 74 years old. Randomized controlled trial was conducted on 76, 693 men in ten centers in the U.S. The intervention, outcomes and participants follow-up of the trial are discussed. It was concluded that annual screening with prostate-specific antigen testing and digital rectal examination did not reduce mortality from prostate cancer for men in the age group of 55 to 74 years old.


Related Articles

  • Annual screening for prostate cancer did not reduce mortality from prostate cancer.  // Evidence Based Medicine;Aug2009, Vol. 14 Issue 4, p104 

    The article examines the effectiveness of annual screening for prostate cancer in reducing mortality rate. Based on randomised controlled trials conducted to 76,693 men ranging from 55 to 74-years-old was considered to be a positive result. Meanwhile, the result shows that the incidence and...

  • Periodic screening with prostate-specific antigen testing reduced mortality from prostate cancer. Canfield, Steven E. // ACP Journal Club;6/23/2009, Vol. 150 Issue 6, p3 

    The article discusses whether constant screening for prostate cancer in men with prostate-specific antigen testing reduce mortality from prostate cancer. Randomized controlled trial was conducted on 1,62, 243 men aged 55 to 69 years in seven European countries. The intervention, outcomes and...

  • Prostate-Specific Antigen Screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer–Rotterdam. Wever, Elisabeth M.; Draisma, Gerrit; Heijnsdijk, Eveline A. M.; Roobol, Monique J.; Boer, Rob; Otto, Suzie J.; De Koning, Harry J. // JNCI: Journal of the National Cancer Institute;3/3/2010, Vol. 102 Issue 5, p352 

    Dissemination of prostate-specific antigen (PSA) testing in the United States coincided with an increasing incidence of prostate cancer, a shift to earlier stage disease at diagnosis, and decreasing prostate cancer mortality. We compared PSA screening performance with respect to prostate cancer...

  • Probability, Uncertainty, and Prostate Cancer. Concato, John // Annals of Internal Medicine;2/5/2013, Vol. 158 Issue 3, p211 

    An introduction is presented in which the editor discusses two randomized controlled trials of screening for prostate cancer.

  • Screening for Prostate Cancer Using Prostate-specific Antigen Alone as a First-line Checkup Parameter: Results of the Health Checkup System. Uchida, Katsunori; Takeshima, Hitoshi; Akaza, Hideyuki; Ono, Yukio // Japanese Journal of Clinical Oncology;Feb2000, Vol. 30 Issue 2 

    Discusses the results of primary prostrate cancer screening using serum prostrate-specific antigen (PSA) levels in a health checkup system in Japan. Cut-off value for PSA; Detection rates of prostrate cancer; Screening by digital rectal examination and transrectal ultrasonography; Usefulness of...

  • Quality-of-Life Effects of Prostate-Specific Antigen Screening. Heijnsdijk, Eveline A.M.; Wever, Elisabeth M.; Auvinen, Anssi; Hugosson, Jonas; Ciatto, Stefano; Nelen, Vera; Kwiatkowski, Maciej; Villers, Arnauld; P�ez, Alvaro; Moss, Sue M.; Zappa, Marco; Tammela, Teuvo L.J.; M�kinen, Tuukka; Carlsson, Sigrid; Korfage, Ida J.; Essink-Bot, Marie-Louise; Otto, Suzie J.; Draisma, Gerrit; Bangma, Chris H.; Roobol, Monique J. // New England Journal of Medicine;8/16/2012, Vol. 367 Issue 7, p595 

    Background: After 11 years of follow-up, the European Randomized Study of Screening for Prostate Cancer (ERSPC) reported a 29% reduction in prostate-cancer mortality among men who underwent screening for prostate-specific antigen (PSA) levels. However, the extent to which harms to quality of...

  • Active Surveillance for Prostate Cancer. Thompson, Ian M.; Klotz, Laurence // JAMA: Journal of the American Medical Association;12/1/2010, Vol. 304 Issue 21, p2411 

    The authors reflect on the active surveillance approach in preventing, diagnosing and treating prostate cancer. They note that active surveillance with treatment reserved for evidence of rapid prostate-specific antigen (PSA) progression or increase in tumor volume or grade is associated with...

  • Prostate cancer: to screen or not to screen? Schroder, Fritz H. // BMJ: British Medical Journal (International Edition);2/13/93, Vol. 306 Issue 6875, p407 

    Examines the diagnosis of prostate cancer. Percentage of mortality caused by the disease; Treatment of cancer; Identification of cancers discovered at necropsy.

  • Improving the pre-screening of eligible patients in order to increase enrollment in cancer clinical trials. Campillo-Gimenez, Boris; Buscail, Camille; Zekri, Oussama; Laguerre, Brigitte; Le Prisé, Elisabeth; De Crevoisier, Renaud; Cuggia, Marc // Trials;2015, Vol. 16 Issue 1, p304 

    Background The performance of randomized controlled trials (RCTs) is often hindered by recruitment difficulties. This study aims to explore the pre-screening phase of four prostate cancer RCTs to identify the impact of a systematic pre-selection of eligible patients for RCT recruitment. Methods...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics